Is molecular “pharming” a potential hazard tothe environment?

Guenther Stotzky, Deepak Saxena

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Plants and animals are being genetically engineered as “biofactories” (“pharms”) to express a spectrum of biomolecules (e.g., antibodies, vaccines, hormones, blood substitutes, toxins, other pharmaceuticals) for numerous therapeutic purposes, as well as for industrial uses (e.g., enzymes). The release to the environment of these transgenic organisms, which contain foreign genes from human beings, other animals, and other organisms, may pose a hazard to the environment. For example, the continual production of these biomolecules in the tissues of plants could result in their accumulation to concentrations that may constitute a hazard to other organisms in soil, waters, and other ecosystems into which the biomolecules will be released in root exudates, biomass, pollen, etc. Accumulation, as well as persistence, will be enhanced if these biomolecules are bound on surface-active particles (e.g., clays, humic substances) in the environment and, thereby, are rendered less accessible for microbial degradation, as has been shown for the insecticidal proteins from Bacillus thuringiensis, which retain toxicity when bound.

Original languageEnglish (US)
Title of host publicationEnvironmental Impact Assessments
PublisherNova Science Publishers, Inc.
Pages77-86
Number of pages10
ISBN (Electronic)9781617284106
ISBN (Print)9781606926673
StatePublished - Jan 1 2009

Fingerprint

molecular farming
hazard
organisms
Genetically Modified Organisms
Humic Substances
Blood Substitutes
insecticidal proteins
Bacillus thuringiensis
Genetically Modified Animals
animal
humic substances
root exudates
vaccine
Exudates and Transudates
Pollen
humic substance
biodegradation
Biomass
toxin
antibody

Keywords

  • Bacillus thuringiensis
  • Biofactories
  • Biomass degradation
  • Biomolecules
  • Clays
  • Cry proteins
  • Humic acids
  • Pharmaceuticals
  • Transgenic plants

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Environmental Science(all)

Cite this

Stotzky, G., & Saxena, D. (2009). Is molecular “pharming” a potential hazard tothe environment? In Environmental Impact Assessments (pp. 77-86). Nova Science Publishers, Inc..

Is molecular “pharming” a potential hazard tothe environment? / Stotzky, Guenther; Saxena, Deepak.

Environmental Impact Assessments. Nova Science Publishers, Inc., 2009. p. 77-86.

Research output: Chapter in Book/Report/Conference proceedingChapter

Stotzky, G & Saxena, D 2009, Is molecular “pharming” a potential hazard tothe environment? in Environmental Impact Assessments. Nova Science Publishers, Inc., pp. 77-86.
Stotzky G, Saxena D. Is molecular “pharming” a potential hazard tothe environment? In Environmental Impact Assessments. Nova Science Publishers, Inc. 2009. p. 77-86
Stotzky, Guenther ; Saxena, Deepak. / Is molecular “pharming” a potential hazard tothe environment?. Environmental Impact Assessments. Nova Science Publishers, Inc., 2009. pp. 77-86
@inbook{1e18ff05164a4e11b76634fbc5e37c7b,
title = "Is molecular “pharming” a potential hazard tothe environment?",
abstract = "Plants and animals are being genetically engineered as “biofactories” (“pharms”) to express a spectrum of biomolecules (e.g., antibodies, vaccines, hormones, blood substitutes, toxins, other pharmaceuticals) for numerous therapeutic purposes, as well as for industrial uses (e.g., enzymes). The release to the environment of these transgenic organisms, which contain foreign genes from human beings, other animals, and other organisms, may pose a hazard to the environment. For example, the continual production of these biomolecules in the tissues of plants could result in their accumulation to concentrations that may constitute a hazard to other organisms in soil, waters, and other ecosystems into which the biomolecules will be released in root exudates, biomass, pollen, etc. Accumulation, as well as persistence, will be enhanced if these biomolecules are bound on surface-active particles (e.g., clays, humic substances) in the environment and, thereby, are rendered less accessible for microbial degradation, as has been shown for the insecticidal proteins from Bacillus thuringiensis, which retain toxicity when bound.",
keywords = "Bacillus thuringiensis, Biofactories, Biomass degradation, Biomolecules, Clays, Cry proteins, Humic acids, Pharmaceuticals, Transgenic plants",
author = "Guenther Stotzky and Deepak Saxena",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781606926673",
pages = "77--86",
booktitle = "Environmental Impact Assessments",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Is molecular “pharming” a potential hazard tothe environment?

AU - Stotzky, Guenther

AU - Saxena, Deepak

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Plants and animals are being genetically engineered as “biofactories” (“pharms”) to express a spectrum of biomolecules (e.g., antibodies, vaccines, hormones, blood substitutes, toxins, other pharmaceuticals) for numerous therapeutic purposes, as well as for industrial uses (e.g., enzymes). The release to the environment of these transgenic organisms, which contain foreign genes from human beings, other animals, and other organisms, may pose a hazard to the environment. For example, the continual production of these biomolecules in the tissues of plants could result in their accumulation to concentrations that may constitute a hazard to other organisms in soil, waters, and other ecosystems into which the biomolecules will be released in root exudates, biomass, pollen, etc. Accumulation, as well as persistence, will be enhanced if these biomolecules are bound on surface-active particles (e.g., clays, humic substances) in the environment and, thereby, are rendered less accessible for microbial degradation, as has been shown for the insecticidal proteins from Bacillus thuringiensis, which retain toxicity when bound.

AB - Plants and animals are being genetically engineered as “biofactories” (“pharms”) to express a spectrum of biomolecules (e.g., antibodies, vaccines, hormones, blood substitutes, toxins, other pharmaceuticals) for numerous therapeutic purposes, as well as for industrial uses (e.g., enzymes). The release to the environment of these transgenic organisms, which contain foreign genes from human beings, other animals, and other organisms, may pose a hazard to the environment. For example, the continual production of these biomolecules in the tissues of plants could result in their accumulation to concentrations that may constitute a hazard to other organisms in soil, waters, and other ecosystems into which the biomolecules will be released in root exudates, biomass, pollen, etc. Accumulation, as well as persistence, will be enhanced if these biomolecules are bound on surface-active particles (e.g., clays, humic substances) in the environment and, thereby, are rendered less accessible for microbial degradation, as has been shown for the insecticidal proteins from Bacillus thuringiensis, which retain toxicity when bound.

KW - Bacillus thuringiensis

KW - Biofactories

KW - Biomass degradation

KW - Biomolecules

KW - Clays

KW - Cry proteins

KW - Humic acids

KW - Pharmaceuticals

KW - Transgenic plants

UR - http://www.scopus.com/inward/record.url?scp=84936962130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936962130&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84936962130

SN - 9781606926673

SP - 77

EP - 86

BT - Environmental Impact Assessments

PB - Nova Science Publishers, Inc.

ER -